Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trialMin Yan, Huajun Li, Yajing Feng et al.|Nature Communications|2023Cited by 14
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trialMin Yan, Fangzhou Xia, Huawu Xiao et al.|EClinicalMedicine|2024Cited by 10
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.Min Yan, Yajing Feng, Huimin Lv et al.|Journal of Clinical Oncology|2024Cited by 7
Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases.Min Yan, Ruoyu Huang, Huimin Lv et al.|Journal of Clinical Oncology|2024Cited by 5
Utidelone Plus Bevacizumab for <i>ERBB2</i>-Negative Metastatic Breast Cancer and Active Brain MetastasesMin Yan, Rongguo Qiu, Huimin Lv et al.|JAMA Oncology|2025Cited by 4